635325-08-5

Usage

Chemical classification

Ethyl ester derivative of pyrazolo[3,4-b]pyridine carboxylic acid with a substituted hydrazino group.

Pharmacological applications

Potential tyrosine kinase inhibitor with promising anticancer, antiviral, anti-inflammatory, and immunomodulatory effects.

Preclinical studies

Demonstrated anticancer, antiviral, anti-inflammatory, and immunomodulatory properties.

Potential therapeutic uses

Treatment of various inflammatory and autoimmune diseases, as well as cancer and viral infections.

Further research

Necessary to fully understand the medicinal potential and mechanisms of action of 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[2-(3-fluorophenyl)hydrazino]-6,7-dihydro-1-methyl-6-oxo-, ethyl ester.

Upstream product

• 66857-96-3 ethyl 4-hydroxy-1-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-carboxylate 
• 105-53-3 diethyl malonate 
• 31037-02-2 ethyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate 
• 658-27-5 m-fluorophenylhydrazine 
• 635325-01-8 ethyl 4-chloro-1-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-carboxylate 

Downstream Products

• 635325-09-6 2-(3-fluorophenyl)-6-methyl-1,2,5,6-tetrahydro-1,2,5,6,7-pentaza-as-indacene-3,4-dione 

Relevant academic research and scientific papers

Dihydrodipyrazolopyridinone inhibitors of B7-1

The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease.

Structure-activity studies of a series of dipyrazolo[3,4-b:3′,4′-d]pyridin-3-ones binding to the immune regulatory protein B7.1

The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. Herein, we report the identification of potent small molecule inhibitors of the B7.1-CD28 interaction. In a high-throughput screen we identified several leads that prevented the interaction of B7.1 with CD28 with activities in the nanomolar to low micromolar range. One of these, the dihydrodipyrazolopyridinone 1, was subsequently shown to bind the V-like domain of human B7.1 at equimolar stoichiometry. With this as a starting point, we report here the synthesis and initial in vitro structure-activity relationships of a series of these compounds.